The Finance Ministry claimed the initiative will cost approximately 50,000 crores and that the government has the funds, a day after Prime Minister Narendra Modi announced that the Centre will take back vaccine-buying from states. “We don’t need to apply for supplemental subsidies right away because we have enough money. We may have to go for it in the second round, at the end of Parliament’s winter session. We currently have the funds “According to officials in the Finance Ministry,
According to the sources, the government is no longer relying on imported vaccinations to fulfill its immunization requirements.
“Our procurement programme is centered around Bharat Biotech, Serum Institute, and the new Bio-E; with these vaccines, we will be able to deliver vaccines for a significant population,” sources added.
Talks with Pfizer and Moderna are apparently stalled due to the vaccine makers’ indemnification demand and their desire that any issues in India involving their vaccines be resolved in US courts solely.
“At the moment, Moderna has no plans to enter until January next year,” according to sources in the Finance Ministry.
In addition to Covaxin from Bharat Biotech and Covishield from the Serum Institute of India, Russia’s Sputnik V has been approved for usage in India.
Sputnik, on the other hand, “will not be large,” according to authorities, who added, “We haven’t started procurement for this yet.”
Last week, the government said that it has reserved 30 crore doses of Biological-Covid E’s vaccine, which is still in clinical studies. After Covaxin, the Health Ministry will give a 1,500 crore advance payment to the business for what will be the second made-in-India vaccine.
According to sources, the decision has been made to distribute Dearness Allowance to central government employees prospectively, rather than retroactively with arrears, beginning July 1.
“We can’t have both a free vaccine and a retroactive rise in Dearness Allowance. We must prioritize and choose what is most vital “officials have stated.